98%
921
2 minutes
20
Non-follicular low-grade B-cell lymphomas (LGBCL) are biologically diverse entities that share clinical and histologic features that make definitive pathologic categorization challenging. While most patients with LGBCL have an indolent course, some experience aggressive disease, highlighting additional heterogeneity across these subtypes. To investigate the potential for shared biology across subtypes, we performed RNA sequencing and applied machine learning approaches that identified five clusters of patients that grouped independently of subtype. One cluster was characterized by inferior outcome, upregulation of cell cycle genes, and increased tumor immune cell content. Integration of whole exome sequencing identified novel LGBCL mutations and enrichment of TNFAIP3 and BCL2 alterations in the poor survival cluster. Building on this, we further refined a transcriptomic signature associated with early clinical failure in two independent cohorts. Taken together, this study identifies unique clusters of LGBCL defined by novel gene expression signatures and immune profiles associated with outcome across diagnostic subtypes.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10592585 | PMC |
http://dx.doi.org/10.1002/hon.3187 | DOI Listing |
NMC Case Rep J
August 2025
Department of Pathology, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Composite or collision tumors in the central nervous system can significantly impact disease progression and metastasis, potentially affecting treatment efficacy. Studying the mechanisms associated with these tumors can provide neuro-oncologists with insights into tumor diversity, progression, and aid in the development of novel treatments. We encountered an 84-year-old female with memory disturbance who presented with tumors consistent with wild-type isocitrate dehydrogenase high-grade glioma and low-grade B-cell lymphoma at the same site.
View Article and Find Full Text PDFHum Pathol
August 2025
Department of Pathology, The Third Affiliated Hospital of Southern Medical University, Guangzhou, China. Electronic address:
Previous studies have confirmed that insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) is widely expressed in various malignant tumors. However, no systematic study has assessed the expression of IMP3 in bone tumors. We immunohistochemically examined 1381 bone tumor specimens for IMP3 expression, analyzed its differential expression among various types of bone tumors, and evaluated its potential application in surgical pathology.
View Article and Find Full Text PDFMed Sci (Basel)
July 2025
Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya 60286, Indonesia.
Aging is associated with complex immune dysfunction that contributes to the onset and progression of the "geriatric giants", including frailty, sarcopenia, cognitive decline, falls, and incontinence. Central to these conditions is immunosenescence, marked by thymic involution, the loss of naïve T cells, T-cell exhaustion, impaired B-cell class switch recombination, and increased autoreactivity. Concurrently, innate immunity deteriorates due to macrophage, neutrophil, and NK cell dysfunction, while chronic low-grade inflammation-or "inflammaging"-amplifies systemic decline.
View Article and Find Full Text PDFDiagn Cytopathol
August 2025
Dubai Hospital, Dubai, UAE.
Compared to myelomatous effusions, there is a lack of studies that specifically address hematolymphoid plasmacytic effusions (HPEs). We conducted a retrospective review study over 15 years to investigate the prevalence, cytologic patterns, potential interpretation pitfalls, and clinical associations of HPEs. Serous effusion fluids in which plasmacytoid and plasma cells represented more than 10% of effusion cells were classified as HPEs.
View Article and Find Full Text PDFGan To Kagaku Ryoho
July 2025
Advanced Clinical Research Center, Fukushima Global Medical Science Center, Fukushima Medical University.
Nuclear medicine treatment is a treatment in which RI is administered to patients, and hematopoietic tumors were treated with 90Y-conjugated anti-CD20 antibodies for low-grade B-cell lymphoma from 2008 to 2021. Targeted α-particle therapy has attracted attention because they have a remarkable therapeutic effect and is effective in cases refractory to β-particle therapy. In Japan, astatine-211(211At)-labeled drugs are being developed due to the restriction of the production and supply of actinium-225(225Ac).
View Article and Find Full Text PDF